CAR T-Cell Therapy in Israel
CAR T-cell therapy is a revolutionary, highly specialized and individualized treatment for leukemia and lymphoma (“blood cancer”) offered by a limited number of cancer centers worldwide. We are pleased to offer CAR T-cell therapy to patients from the UAE, at the Sheba Medical Center’s Hemato-Oncology Department. Our campus is located in closer proximity to the UAE than Europe and the United States, with new treatment solutions that are more affordable.
CAR T-cell therapy transforms the patient’s own white blood cells, programming them to kill cancer cells. It has led to many positive outcomes, putting cancer into remission in many patients who did not respond to other treatment methods. At Sheba, we have all of the advanced facilities necessary for delivering CAR T-cell therapy, including a laboratory to engineer the T-cells.
CAR T-cell Therapy Work?
CAR-T treatment for leukemia and lymphoma is an innovative process that uses your own immune cells to seek and destroy cancerous cells.
Blood is taken from the patient, and advanced technology is used to separate the white blood cells (an essential part of the immune system) from the rest of the blood cells. The white blood cells are then sent to a specialized laboratory, where they are engineered to produce specific chimeric antigen receptors (CARs) on their surface. These CAR T-cells are then reinjected back into the patient’s bloodstream. Now, the new CARs can help the modified cells latch on to the coordinating antigen on tumor cells – effectively hunting down and killing cancerous cells.
While the modified T-cells grow in our laboratory, the patient receives chemotherapy to suppress their immune system, creating a more efficient setting for the CAR T-cells to do their job and eliminate malignant cells.
A significant benefit of CAR T-cell therapy is that it not only instructs the T-cells to kill the cancer, but it also triggers the T-cells to grow and multiply. Therefore, after just one treatment, the cells continue to attack the tumor for months or even years.
Who Can Receive
CAR T-cell Therapy in Israel?
Potential patients need to have undergone at least two prior cancer treatments for cancer of the blood (certain types of leukemia and lymphoma) that have failed. We offer a full diagnostic procedure to determine whether CAR T-cell therapy is a suitable option.
Sheba is excited to announce that it now offers the innovative CAR T-cell therapy for patients with multiple myeloma and is the first medical center in the world to pioneer its application for acute myeloid leukemia (AML) with 8:21 translocation and CD19 expression.
Great success has been achieved in young patients with CAR-T treatment. Complete recovery has been observed in:
85-90% of young children
Approximately 80% of teenagers
Around 70% of the entire patient population
Sheba continues to strive to further improve these rates through ongoing research and by retaining the best physicians.
Why Come to
Sheba Medical Center
from the UAE?
Presently, the UAE sends many complicated patient cases to other countries, and now, Sheba offers a solution that is closer than Europe and more affordable than the United States. Many members of the medical staff also speak Arabic, creating a comfortable atmosphere – like a home away from home.
CAR T-cell therapy in Israel provides patients from the UAE with a personalized, advanced treatment administered by world-renowned cancer specialists. Not only is Sheba the largest, most comprehensive hospital in the Middle East, but for the past two years it was ranked by Newsweek as one of the top 10 hospitals in the world. As a leading international force in medicine and biotechnological innovation, Sheba offers many treatments and technologies that are unavailable elsewhere. Presidents, VIPs and top-level executives regularly choose Sheba for medical treatment.
Joining forces to advance patient care: Sheba Medical Center and APEX National Investment, based in Abu Dhabi, recently signed a memorandum of agreement, laying the groundwork for medical tourism, medical training and digital healthcare innovation. To encourage startups, Sheba and APEX will set up a collaborative healthcare hub for the UAE modeled after the ARC Innovation Center on Sheba’s campus in Israel.
Benefits of CAR T-cell Therapy at Sheba
Convenient on-site care We feature full CAR-T facilities under one-roof (including cell harvesting, chemotherapy, genetic engineering laboratory, T-cell injections, and patient observation), creating an efficient experience.
Affordable fees Medical expenses are generally lower than in the US, and we offer full transparency with no hidden costs
World-renowned specialists Our staff includes some of the most qualified and experienced oncologists, hematologists, and immunologists in the world
Full accreditation We are fully accredited for international healthcare by the Joint Commission International (JCI)
Patient- friendly A coordinator from the International Medical Tourism Division will assist with everything from travel to translation
Holistic care Healthcare at Sheba is provided with a holistic approach; treatments are designed to take the patient’s quality of life and overall well-being into consideration
Sam Turel’s Treatment with CAR-T Therapy
In his native India, Sam Turel began receiving treatments in 2009 for chronic lymphocytic leukemia (CLL). After spending seven years in remission, he suffered a relapse and was treated with targeted therapy. Unfortunately, his cancer took a turn for the worse and transformed from CLL to diffuse large b-cell lymphoma (DLBCL), and attempts to treat it with chemotherapy failed. That was when Sam began to research other options, and he turned to Sheba Medical Center for CAR T-cell therapy. Now, he is happy to be enjoying his retirement years
Prof. Arnon Nagler, MD
Director of the Division of Hematology, Director of Bone Marrow Transplantation and Cord Blood Bank
Prof. Nagler specializes in hematology, bone marrow transplantation, and internal medicine. He has pioneered numerous treatments for malignant and non-malignant blood disorders in Israel. He established the first public cord blood bank at Sheba in 2001, and he performed the first cord blood transplantation in Israel. In addition to his role at Sheba Medical Center, Prof. Nagler is a Professor of Medicine at Tel-Aviv University.
Prof. Nagler received his medical degree from the Hebrew University – Hadassah Medical School, in Jerusalem, Israel, and then completed a postdoctoral fellowship at Stanford University, in the United States. In addition to receiving numerous awards, he is widely published and a world-renowned speaker. Prof. Nagler has also holds over 40 patents and trademarks. He is a member of the EHA Scientific Program Committee, and Chair of the European Leukemia Subcommittee on Transplantation.
Holistic healing at sheba
When providing TIL immunotherapy in Israel, we consider all aspects of each patient’s overall wellness and quality of life, including physical, emotional, and social needs. We aim to create the most customized, comfortable and efficient experience possible, with all-inclusive services, such as psychology, social services, beneficial complementary medicine, and palliative care offered under one roof on our vast campus. Every patient is also assigned a personal medical coordinator from the International Medical Tourism Division, who provides assistance throughout every step of the treatment.
Ranked In ThE TOP TEN
Best Hospitals Worldwide
Sheba Medical Center sets the standard for excellence in patient-focused care. Recently, Newsweek included Sheba on their prestigious list of the Top Ten Best Hospitals Worldwide. This endorsement recognizes Sheba as a leading force in medical science and biotechnological innovation – maximizing the latest technologies while always providing holistic, outstanding healthcare. Sheba is strongly committed to delivering personalized, expert medicine to everyone from all over the world.